- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 06.11. | Trump claims comprehensive victory in US election | ||
| 06.11. | Wegovy romps ahead after key rival sees slowdown | ||
| 06.11. | Beam points to positive data with key base editing asset | ||
| 06.11. | AZ shares weaken as China investigation rumours swirl | ||
| 05.11. | Journey slips on FDA approval of rosacea therapy | ||
| 05.11. | CRUK backs AI-powered, virtual radiotherapy trial projects | ||
| 05.11. | Disc maps out US filing for porphyria drug bitopertin | ||
| 05.11. | NICE backs first ophthalmic bevacizumab for NHS use | ||
| 05.11. | Novo puts $285m into monthly GLP-1 based on Ascendis tech | ||
| 04.11. | Incyte blocks US launch of Sun Pharma's alopecia drug | ||
| 04.11. | NHS pilots iPhone app to rule out throat cancer | ||
| 04.11. | Accord will build £50m manufacturing plant in UK | ||
| 04.11. | Pharmas ask appeals court to reconsider IRA lawsuits | ||
| 04.11. | Novo Nordisk will file semaglutide for MASH next year | ||
| 01.11. | Lexicon's type 1 diabetes drug voted down by FDA adcomm | ||
| 01.11. | NICE trumpets new standard for health AI evaluations | ||
| 01.11. | Eisai, Biogen eye 2025 approval for Leqembi autoinjector | ||
| 31.10. | Teva fined €462.6m for antitrust delay to MS drug rivals | ||
| 31.10. | Compass points to job cuts as it defers trial readouts | ||
| 31.10. | Lexeo shares dip on early data with Alzheimer's gene therapy | ||
| 31.10. | Nasdaq debutante Septerna swells its IPO to $331m | ||
| 31.10. | Alpha-9's $175m third-round heads latest biotech financings | ||
| 31.10. | AZ confirms its China president is under investigation | ||
| 30.10. | UK Chancellor pledges £22bn rise in day-to-day NHS spending | ||
| 30.10. | Novartis gets FDA okay for frontline use of Scemblix in CML |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
